Dendreon dendreon.com


Public list: Pharma Startups (4740) Cancer Therapeutics (1146)

Dendreon is a biopharmaceutical company targeting cancer through the discovery, development, commercialization, and manufacturing of novel therapeutics. Its product Provenge is an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.

Dendreon is a biopharmaceutical company targeting cancer through the discovery, development, commercialization, and manufacturing of novel therapeutics. Its product Provenge is an autologous cellular immunotherapy for the treatment of asymptomatic or...Show all

Company (Acquired)

Phone: 877-256-4545

Fax:

1208 Eastlake Avenue East

Seattle, 98102
Washington, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Dendreon $124.3M Jan 10, 2017
Threshold Pharmaceuticals $106.4M Aug 2, 2017
Bioheart $43.1M Mar 31, 2011
See all 34 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Dendreon Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 11 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors
See all 34 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Compositions employing alternative reading frame polypeptides for the treatment of cancer and infectious disease Oct 05, 2009 Jun 09, 2015 Patent
Promiscuous her-2/neu cd4 t cell epitopes Aug 16, 2012 Feb 25, 2014 Patent
Promiscuous pap cd4 t cell epitopes Jan 04, 2013 Feb 11, 2014 Patent
Small-molecule modulators of trp-p8 activity Aug 09, 2010 Dec 31, 2013 Patent
Small-molecule modulators of trp-p8 activity Jun 08, 2010 Dec 24, 2013 Patent
See all 26 patents